Information Letter of the ELN: Editor Statements

Please read and send/fax your agreement (2 pages) back to:

European Leukemia Information Center ELIC
Dr. N. Gökbuget / A. Hellenbrecht / K. Ihrig
University Clinic of Frankfurt
Dept. of Hematology / Oncology
Theodor-Stern Kai 7
60590 Frankfurt am Main, Germany
Phone: +49(0)69 6301 -6365
Fax: +49-(0)69 6301 -7463
E-mail: elic@leukemia-net.org
Internet: www.leukemia-net.org
www.kompetenznetz-leukaemie.de

1. Basic Information

The IL presents results from the collaboration of transnational leukemia study groups. This is not only of interest for clinicians and researchers in the field of hematology throughout Europe, but also worldwide. Major goals are target and drug discovery, support of clinical translation, application of genomics and promotion of clinical trials. Furthermore, meta-analyses, elaboration of prognostic scores and guidelines for diagnostics and treatment will be promoted throughout Europe. Authors are invited by the Editorial Board and are following the Editor statements (signed agreement of the responsible authors).

2. Informed Consent

Identifying information, including patients' names, initials, or hospital numbers, are not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published. Authors have to identify Individuals who provide writing assistance and disclose the funding source for this assistance.

Identifying details should be omitted if they are not essential and informed consent should be obtained if there is any doubt about anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors have to provide assurance that alterations do not distort scientific meaning.

3. Conflict of interest

It has been the policy of the European LeukemiaNet not to promote the pharmaceutical industry, their products and/or services in the IL for advertisement. The selection and review of authors articles are free of influence by financial or personal relationships of the Editorial Board. Authors are asked about having conflict of interest regarding the research project. If a conflict of interest of the author is possible, this will be published.
4. Human and animal rights

When reporting experiments on human subjects, authors have to indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors are asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed and this will be published.

5. Editorial Board

Marie C. Béné
Steven O’Brien
Alan Burnett
Guido Finazzi
Christa Fonatsch
Eliane Gluckman
Nicola Gökbuget (Editor-in-Chief)
David Grimwade
Torsten Haferlach
Michael Hallek
Jörg Hasford
Rüdiger Hehlmann
Dieter Hoelzer (Editor-in-Chief)
Per Ljungmann
Dietger Niederwieser
Susanne Saussele
Hubert Serve
Bengt Simonsson
Theo J. M. de Witte

6. Agreement:

As an author of the Information Letter of the European LeukemiaNet (ELN), I agree, to follow these editor statements of the Information Letter of the ELN.

Name:

______________________________________________________________________________

date sign